Vanguard Capital Management
RYTM icon

Vanguard Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Vanguard Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$286M Sell
3,005,450
-527
-0% -$56.2K 0.01% 898
2026
Q2 		$334M Buy
3,005,977
+38,152
+1% +$3.45M 0.01% 861
2026
Q1 		$258M Buy
+2,967,825
New +$289M 0.01% 933

Other funds holding RYTM

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $442M AUM 36.72% 1-Year Est. Return

Vanguard Capital Management's RYTM Position: Q3 2026 in Review

Vanguard Capital Management reduced its Rhythm Pharmaceuticals (RYTM) stake by 0.02% in Q3 2026, selling an estimated $56.2K and leaving 3,005,450 shares worth $286M. The position accounts for 0.01% of the portfolio, ranked #898.

Vanguard Capital Management first reported a position in RYTM in Q1 2026 and has held it in 3 quarters since. The position peaked at $334M in Q2 2026. 239 funds tracked by Wall St. Rank hold RYTM as of Q3 2026.

  • Vanguard Capital Management held 3,005,450 shares of Rhythm Pharmaceuticals worth $286M as of Q3 2026.
  • Vanguard Capital Management sold 527 Rhythm Pharmaceuticals shares in Q3 2026, an estimated $56.2K.
  • Rhythm Pharmaceuticals made up 0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #898 holding.
  • Vanguard Capital Management first reported a position in Rhythm Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Rhythm Pharmaceuticals position peaked at $334M in Q2 2026.
  • 239 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.